Isfahan Gastroenterology and Hepatology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Syst Rev. 2024 Feb 26;13(1):76. doi: 10.1186/s13643-024-02489-1.
Evidence on the effects of bovine colostrum (BC) supplementation on gastrointestinal (GI) diseases is conflicting.
This systematic review summarized the findings of clinical trials (CTs) on the effects of BC supplementation on GI diseases.
A systematic search was conducted in online databases, including PubMed, ISI Web of Science, and Scopus, until March 2021 and updated until December 2023. CTs investigated BC's effect on any measurable symptomatic change in terms of GI health as the primary outcome variable or as one of the outcomes in any population eligible for this systematic review.
Out of 6881 records, 22 CTs (uncontrolled = 4, cross-over = 1, and parallel = 17) with 1427 patients were enrolled in the systematic review. Diarrhea, the most frequently evaluated symptom (20 interventional arms), was decreased in frequency with BC supplementation in 15 of these arms. However, most studies reported no change in its duration. BC supplementation consistently reduced stool frequency across all seven studies. Abdominal pain relief was noted in four interventional arms but showed no improvement in five others. Assessment of other GI symptoms was limited, yielding inconclusive results.
There is limited evidence on the effects of BC on GI diseases, with mixed findings. More well-designed controlled clinical trials are required to explore its effects.
关于牛初乳（BC）补充剂对胃肠道（GI）疾病影响的证据相互矛盾。
本系统综述总结了临床试验（CT）关于 BC 补充剂对 GI 疾病影响的研究结果。
系统检索了在线数据库，包括 PubMed、ISI Web of Science 和 Scopus，检索时间截至 2021 年 3 月，并更新至 2023 年 12 月。CT 研究以 GI 健康方面任何可衡量的症状变化（作为主要结局变量或系统综述纳入人群的结局之一）为主要结局变量，研究 BC 对任何人群的影响。
在 6881 条记录中，有 22 项 CT 研究（非对照=4 项，交叉=1 项，平行=17 项）纳入了 1427 名患者。腹泻是最常评估的症状（20 个干预组），其中 15 个干预组中腹泻频率降低。然而，大多数研究报告其持续时间没有变化。BC 补充剂在所有 7 项研究中均一致降低了粪便频率。4 个干预组中观察到腹痛缓解，但在另外 5 个组中未见改善。对其他胃肠道症状的评估有限，结果不一致。
关于 BC 对 GI 疾病影响的证据有限，结果不一致。需要更多设计良好的对照临床试验来探索其作用。
